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The pre-S-specific monoclonal antibody MA 18/7 has been shown to inhibit the binding of HBV to HepG2 cells and liver
membranes. This antibody can thus be used to identify the critical residues of the pre-S region involved in the hepatocyte-
binding domain. Using overlapping 7-mer peptides representing the pre-S region of HBV, the epitope recognized by MA
18/7 was shown to contain sequences from both the pre-S1 and pre-S2 regions, thus indicating that the hepatocyte-binding
domain is conformationally dependent. To further characterize the primary structure of the hepatocyte-binding domain on
the pre-S protein, a phage-displayed 15-mer peptide library and a 8-mer solid phase peptide library were used to analyze
the fine specificity of the monoclonal antibody MA 18/7. Several mimotopes were identified with the phage-displayed peptide
library, the majority of which possess a central motif with at least three identical residues present within the native pre-S1
sequence. No significant consensus sequences were found when these mimotopes were compared to the pre-S2 sequence.
Mimotopes identified using the solid-phase peptide library also contained a similar motif. All phage mimotopes and a single
mimotope from the solid-phase peptide library competed with recombinant HBsAg particles containing the pre-S1 region
for binding to MA 18/7. Mouse antisera raised against four mimotopes from the phage display library reacted with HBsAg
particles containing pre-S sequences. The data show that the structure of the pre-S molecule around the conserved DPAF
motif in the pre-S region may have a functional role in binding HBV to cellular receptors, and that the central motif identified
in mimotopes of this region may offer a novel strategy target for the improvement of existing hepatitis B vaccines which,
at present, are mostly devoid of pre-S specificities. q 1997 Academic Press
INTRODUCTION assembly. In order to fulfil both these important functions,
the L protein has dual transmembrane topology with the
The Hepatitis B virus (HBV) is the prototype member amino terminal pre-S domains being expressed on both
of the family Hepadnaviridae, a significant cause of acute sides of the viral envelope (Bruss and Vieluf, 1995).
and chronic liver disease in humans (Ganem and Var- The pre-S proteins induce an immune response in pa-
mus, 1987). A single open reading frame (S ORF) codes tients recovering from HBV infection (Neurath and Kent,
for the production of the three HBV envelope proteins. 1987) and are considered to elicit virus neutralizing anti-
The S gene is divided into three regions, pre-S1, pre-S2, body (Neurath et al., 1989). The pre-S1 region is thought
and S, three in-frame translation initiation codons (AUG) to contain the hepatocyte receptor binding site (Neurath
at the beginning of each region being responsible for et al., 1986b). The pre-S region contains epitopes that
the production of the large, middle, and major envelope elicit immune responses at the B-cell and T-cell level
proteins, respectively. The major surface protein (S) is the over a broader range of MHC haplotypes than those on
main component of the 22-nm HBsAg subviral particles the S protein (Milich et al., 1985). The presence of pre-
produced during infection, whereas the pre-S proteins S epitopes, together with those of the S protein, can
which together with S form the large (L) and middle (M) circumvent the nonresponsiveness to the major S protein
envelope proteins are a substantial component of the by providing T-cell help for an anti-HBs antibody re-
virus particle with few, if any, copies present on the subvi- sponse (Milich et al., 1986b, 1987). In mice, nonrespon-
ral particles (Heerman et al., 1984). siveness to S determinants can be overcome by immuni-
The pre-S proteins are thought to play an important zation with both S and pre-S2 determinants (Milich et al.,
role in immunological recognition and in reactions with 1985). Similarly, an anti-HBs response can be induced
virus-specific receptors on hepatocytes. The L protein is in pre-S2 and S nonresponder strains of mice by immuni-
also thought to be involved in the interaction between zation with S, pre-S2, and pre-S1 determinants (Milich et
the viral envelope and the nucleocapsid during virion al., 1986a). Consequently there is a view that the inclu-
sion of pre-S1 and pre-S2 determinants into current HBV
vaccines may reduce the number of human nonrespond-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (/44)-171-383-4670. E-mail: choward@rvc.ac.uk. ers. However, the results from trials with a HBV vaccine
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containing pre-S2 determinants have not supported the virions to HepG2 cells and liver membranes (Budkowska
et al., 1993; Pontisso et al., 1989). Moreover, antibodiesresults in mice (Coursaget et al., 1988; Pillot et al., 1995)
and the inclusion of pre-S1 determinants may also be to a linear peptide representing residues 12–47 from the
pre-S which is recognized by MA 18/7 were shown torequired to improve vaccine efficacy. In a recent study,
69% of individuals who had previously not responded to be virus neutralizing and protective (Neurath et al., 1986b,
1989). Finally, it has been demonstrated that humanvaccines containing S protein only, seroconverted to anti-
HBs antibodies when immunized with a single dose of convalescent HBV sera can compete effectively with MA
18/7 (Deepen et al., 1990), suggesting that the humana recombinant vaccine containing pre-S1, pre-S2, and S
determinants (Zuckerman et al., 1997). This trial empha- immune system can generate antibody of the same
specificity as that represented by the murine antibodysizes the potential of pre-S1 components for improving
seroconversion rates among vaccinated individuals. MA 18/7.
The long term goal of our studies is to develop a totally
synthetic peptide vaccine which can induce an effective MATERIALS AND METHODS
protective immune response against HBV, thereby over-
Monoclonal antibodiescoming some of the deficiencies of the existing hepatitis
B vaccines. These include the poor seroconversion rates The pre-S1 monoclonal antibody MA18/7 (Heerman et
in individuals with natural and acquired immunodefi- al., 1984) and the pre-S2 monoclonal antibody Q19/10
ciency states and the time required for the induction of (Heerman et al., 1988) were kindly provided by Dr. W.
a protective antibody response. Furthermore, most vac- Gerlich (Justus Liebig University, Giessen, Germany).
cines are at present devoid of pre-S specificities, largely Both antibodies were produced after immunization of
due to the difficulties in expressing hepatitis B vaccine mice with HBV virions of the ay subtype. The pre-S1
particles to include the pre-S amino terminal region. monoclonal antibody 5a-19-1 and pre-S2 monoclonal an-
Given the importance of pre-S region in immunity and tibodies F124 and F376 were a kind gift from Dr. A. Bud-
protection, the identification of critical B-cell epitopes is kowska (Institute Pasteur, France). Monoclonal antibod-
clearly of paramount importance in the design of novel ies 5a-19-1 (Budkowska et al., 1995) and F124 (Budkow-
hepatitis B vaccines as well as providing further insight ska et al., 1987) were produced after immunization of
into HBV pathogenesis and immunity. HBV virions of the ay subtype, and F376 (Neurath et al.,
The pre-S region has been extensively analyzed using 1986a) and F.5.2 were produced after immunization of
synthetic peptides and epitopes have been mapped to recombinant HBsAg particles of the ay subtype. The pre-
residues 15–43 in the pre-S1 region (Neurath and Kent, S2 monoclonal antibody F.5.2 was provided by Dr. A. M.
1987) and residues 120–145 in the pre-S2 region (Milich Petit (INSERM U 131 Clamart, France). The pre-S1 mono-
et al., 1986b). However, these studies examined linear clonal antibody 116-80 and the pre-S2 monoclonal anti-
peptides only, which inevitably limited any conclusions body 50-80 (Mimms et al., 1990) were a kind gift from Dr
regarding the precise location and nature of these B- L. Mimms (Abbott Laboratories, North Chicago, IL).
cell epitopes. In this study two experimental approaches These antibodies were produced after immunization with
were employed in order to define the nature of the pre- HBV virions of the ad (116-80) and ad/ay subtype (50-80).
S B-cell epitopes. First, pepscan analysis (Geysen et al.,
1981) using peptides derived from the pre-S adw2 se- Pepscan plates
quence presented on polyethylene rods was used to ac-
Overlapping synthetic peptides, seven residues incurately define the location and specificity of the B-cell
length representing the entire pre-S region of the adw2epitopes recognized by MA 18/7. Second, an alternative
subtype were prepared using the conventional Fmoc pro-approach has been adopted that relies on the use of
tected OPfp amino acid esters (Millipore, UK) and peps-random peptide libraries displayed on either phage parti-
can plates (Cambridge Research Laboratories, UK) ascles (Scott and Smith, 1990) or a solid phase support
described by Geysen et al. (1981). The peptides were(Lam et al., 1991). Although the pepscan technique pri-
analyzed using a modified ‘‘pepscan’’ ELISA assay asmarily allows for the identification of linear epitopes, the
previously described (Steward et al., 1993).use of combinatorial libraries containing an immense
number of peptide sequences permits the identification Screening of 15-mer phage library
of mimics of conformational-dependent B-cell epitopes
The phage display 15-mer peptide library and Esche-represented by linear sequences. Both techniques were
richia coli K91kan cells was kindly provided by Dr. G.used to map the specificity of pre-S monoclonal antibodie
Smith (University of Missouri, MO). Polystyrene beadsMA 18/7. The selection of this antibody was based on
(149 diameter) were coated with 10 mg/ml antibody in 0.1certain lines of evidence highlighting the importance of
the epitopes it recognizes in the pathogenesis of the M carbonate buffer, pH 9.6, overnight at 47. The beads
were washed in PBS six times, blocked with 5% BSA fordisease and possibly immunity against HBV. The anti-
body MA 18/7 has been shown to prevent binding of HBV 2 hr at 47, dried, and stored at 0207. Two beads were
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incubated for 4 hr with 20 ml of the 15-mer library which peroxidase (Jackson Laboratories, U.S.A.) for 1 hr at 377.
After washing, the plates were incubated in the dark forcontained approximately 21 109 clones. The beads were
then washed repeatedly in Tris-buffered saline (TBS) to 5 min in citric acid-phosphate buffer, pH 5.0, containing
an OPD substrate and hydrogen peroxide. The reactionremove unbound phages, and the bound phages were
subsequently eluted in Tris–glycine buffer, pH 2.0. After was stopped on addition of 2 N H2SO4 and the plates
were read at OD492 .neutralization with 1 M Tris–HCl, pH 9.1, the eluted
phages were concentrated using an Amicon 30-micron
filter and amplified in E. coli K91kan. The amplified Immunization of mice
phages were then harvested by precipitation in 3.3 M
Groups of three female BALB/c mice, 6 to 8 weeksNaCl/16.7% PEG-8000. Two further rounds of biopanning
old, were injected intraperitoneally with either 100 mgwere performed using a fraction of the amplified phages
mimotope peptide or coimmunized with 100 mg of a T-from the previous rounds. During the final round of bio-
helper epitope representing residues 258–277 from thepanning, the phages were eluted from the polystyrene
measles virus fusion protein (Partidos et al., 1992) inbeads using a stepwise decrease in pH. Individual colo-
Freund’s complete adjuvant (FCA) emulsion at a 1:1 ratio.nies containing phages were eluted at pH 2, amplified
Mice were boosted 7 weeks later by the same route andas 20-ml cultures, and the phages were precipitated us-
with the same amount of peptide in an emulsion (1:1) withing 3.75 M ammonium acetate, pH 7, containing 16.7%
incomplete Freund’s adjuvant (FIA). Antibody responsesPEG-8000. DNA was purified from the phages by phenol/
were determined as log10 of antibody titers 2 weeks afterchloroform extraction followed by ethanol precipitation.
the boost. Four weeks later mice were boosted by theThe insert DNA was then sequenced using an AutoRead
same route and amount of peptide in an FIA emulsionsequencing kit (Pharmacia, UK) on an A.L.F. automated
(1:1). The immunogenicity of the phage-displayed mimo-DNA sequencer (Pharmacia).
topes was tested by intraperitoneal immunization of
groups of three female 6- to 8-week-old CBA mice withSynthesis of solid-phase peptide library and selection
a 200-ml emulsion (1:1) in FCA containing 1010 phageof mimotopes
particles per milliliter. Five weeks later, mice were
The synthesis of the solid-phase peptide library and boosted via the same route with 200 ml of emulsion (1:1)
selection of mimotopes was as described previously in FIA containing 5 1 109 phage particles per milliliter.
(Lam et al., 1991; Steward et al., 1993). Antibody levels were determined as log10 values of anti-
body titers obtained 2 weeks after the boost.
Synthetic peptides
Peptide mimotopes were synthesized using the Milli- RESULTS AND DISCUSSION
pore 9050 peptide synthesizer using Fmoc chemistry.
Definition of pre-S determinantsPolyethylene glycol–polystyrene (PEG/PS) resin (with a
0.15-mmol Fmoc amino acid loading) and 0.8-mmol Fmoc- The pepscan analysis of antibody MA 18/7 (Table 1)
protected OPfp amino acid esters (Millipore UK) were confirmed the results of previous studies using overlap-
used. Twenty percent piperidine in DMF was used for ping peptides representing the pre-S region of HBV (Cour-
deprotection. Trifluoroacetic acid with the appropriate saget et al., 1991; Sominskaya et al., 1992), namely that
scavengers was used to cleave the peptides from the the antibody recognized an epitope in the pre-S1 region
resin and remove the side chain protecting groups. Pep- comprising residues 28–37 (HQLDPAFGAN). Addition-
tides were then precipitated and washed three times ally, our results show that MA 18/7 also recognized a
in diethyl-ether and dried. After resuspension in water, second determinant in the pre-S2 region comprising resi-
peptides were freeze-dried. dues 131–141 (LQDPRVRGLYLP) and that these residues
may also contribute to the epitope recognized by antibody
Competition ELISA assay
MA 18/7. This is consistent with results indicating that
antisera against the pre-S (120–145) peptide weakly in-Immulon II ELISA plates were coated with 10 mg/ml
pre-S containing HBsAg in 0.1 M carbonate buffer, pH hibits the interaction between HBV and HepG2 cells. Thus
the pre-S2 sequence 120–145 may either have an auxil-9.6, overnight at room temperature. The plates were
washed three times in PBS/0.05% Tween 20 and then iary role in binding of HBV to hepatocytes or may simply
be located near the binding site in the three-dimensionalincubated in PBS containing 10% fetal calf serum (Gibco-
BRL, UK) for 1 hr at 377. The plates were washed as structure of the pre-S1 protein (Neurath and Kent, 1987).
These two domains are predicted to be spatially adjacentbefore and the peptide mimotopes were diluted in 0.5
log dilutions starting at 1003 M. An equal volume of mono- in the three-dimensional structure of the native protein
(Howard et al., 1991). A second pre-S1 monoclonal anti-clonal antibody MA 18/7 was added to each plate and
the plates were incubated overnight at 47. The plates body 116-80 reacted only with residues 28–35 from the
pre-S1 region using the pepscan assay and did not showwere washed and incubated with goat anti-mouse IgG
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TABLE 1
Reactivity of Pre-S1 and Pre-S2 Specific Monoclonal Antibodies with Synthetic Peptides Representing the Pre-S Region
Amino acid residues of the pre-S
adw2 region recognized by the
Immunogen used for monoclonal antibodies
preparation of monoclonal
Monoclonal antibodies antibodies Isotype Pre-S1 region Pre-S2 region
Pre-S1 specific MA 18/7 HBV particles subtype ayr IgG1 28–37 131–143
monoclonal 5a 19-1 HBV particles subtype ay IgG1 35–43 120–128
antibodies 116-80 HBV particles subtype ad IgG1 28–37
Pre-S2-specific F124 HBV particles subtype ay IgG1 119–128
monoclonal Q19/10 HBV particles subtype adw IgG1 117–128; 131–142
antibodies F376 HBsAg subtype ay IgG1 131–139
F5.2 HBsAg subtype ay IgM 94–108 117–127
50-80 HBV particles subtype ay/ad IgG2a 77–88; 100–110 131–137
significant binding to any other domain (Table 1). Further inskaya et al., 1992; F. D’Mello, unpublished observa-
comparative studies were performed with an extended tions). All contained the core motif DX1X2F, with the se-
set of monoclonal antibodies previously characterized as quences DPVF and DRAF being the most frequent. The
specific for pre-S1 and pre-S2 regions. These results motif DPAF, which is identical to the HBV sequence, and
showed a pattern whereby reactive linear peptide sets the similar motif DPGF, were also represented. Single
clustered into discrete domains (Table 1). With the excep- clones were identified with the related motifs DPSF,
tion of antibodies F.5.2 and 50-80, all of the pre-S2-spe- DLGF, and DSAF. An alignment of these mimotopes with
cific monoclonal antibodies reacted with peptides within the pre-S2 sequence (131–143) recognized by MA 18/7
the N-terminus of pre-S2 (Table 1). Antibody F.5.2 and 50- did not reveal a consensus sequence (data not shown).
80 reacted also with peptide analogues located at the C- Alignments were most frequently seen with the aspartyl-
terminus of the pre-S1 region. proline (DP) doublet at positions 134 and 135, respec-
tively (9 mimotopes). In three cases, there was an addi-
Screening of peptide libraries with antibody MA 18/7 tional alignment with the leucine residue at position 132,
giving a consensus motif of L*DP. An immunoblot assayAn important aspect of the characterization of a mono-
was used to independently test for reactivity of the phageclonal antibody is the determination of its binding site
mimotopes with the selecting monoclonal antibody MAon the antigen. This has been facilitated by the develop-
18/7. All phage isolated after biopanning using the anti-ment of random peptide libraries containing in excess of
body attached to polystyrene beads gave a positive reac-1 1 1010 filamentous phage particles, each displaying a
tion. Selected phage clones with the motifs DPAF, DPGF,unique 15-mer peptide sequence in an immunologically
and DRAF gave clear positive immunoblot reactions. Inactive form on the phage surface (Scott and Smith, 1990).
contrast, clones containing the core motif DPVF boundImportantly, the ligands do not necessarily resemble the
less well (data not shown).native sequences but mimic their binding properties ow-
In order to obtain a completely independent assess-ing to a sufficient similarity in shape. Phage-displayed
ment of peptide specificity, the monoclonal antibody MApeptide sequences that are analogues of the precise
18/7 was also analyzed using an 8-mer solid phase pep-determinant recognized by the pre-S1-specific mono-
tide library prepared on polystyrene resin in bead form,clonal MA 18/7 were selected by repeated rounds of
with each bead coated with a single peptide of randombiopanning by screening a 15-mer random peptide
sequence. Three polystyrene beads that were reactivephage library with the pre-S antibody MA 18/7 as de-
with the monoclonal antibody after the ELISA reactionscribed by Scott and Smith (1990). Approximately 1.2 1
were selected and sequenced. As found previously using1010 phage clones were used in the primary round of
the phage display library, peptide sequences selectedbiopanning. Recovery of phage during the successive
from the solid phase library contained motifs similar torounds of biopanning indicated an enrichment of reactive
the sequence DPAF defined as being essential for MAphage clones. After the third round of biopanning, individ-
18/7 binding (Sominskaya et al., 1992; F. D’Mello unpub-ual phage clones were isolated and the insert DNA was
lished observations); beads 2 and 3 were most similarsequenced. All the phage sequenced had peptide insert
to the core motif recognized by MA 18/7, containing thesequences (Table 2) containing motifs identical, or very
motifs DPGW and DWAF, respectively. The motifs identi-similar to, the sequence DPAF defined as being essential
for the binding of the monoclonal antibody MA 18/7 (Som- fied were DSAQ, which had two residues in common
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TABLE 2
Amino Acid Sequence of Mimotopes Obtained after Selection with Monoclonal Antibody MA 18/7 Using the Phage Displayed Peptide Library
and the Synthetic Peptide Library and Comparison with Native pre-S1 28–35 Amino Acid Sequence
Amino acid sequence of residues 28–35 of the pre-S1 region of HBV
H Q L D P A F G A N
5P1 (7) S D T R G D P V F N L P F Q
5P2 (3) A P V D S V F D R A F S A Y L
5P6 T G L P S S D R A F L V S V S
5P8 L R D P V F N I A A G V A L
PC1 L D D P V F G F A R R V P V
PC3 V G S F F A L G D R A F L G L
PC4 (2) M C A V R D P A F S R S R L S
PC5 (2) L S S A R S P R S L D R A F V
PC9 G G F S S D P G F L L R P R V
PC10 L M D P V F G F D R R V P F
PC12 L L D P S F D Y F Q L Y T T
4P2 D F G P L F S D P G F R S A S
4P3 G P L D R A F S W R L N P R V
PF2 R M C S L D L G F C Q T I L R
PE3 G V R L L S G V F S D P A F A
PE4 L M D P V F G F D R R V P V
PE5 V H L D S A F W F V R T D F D
PE6 G G F S S D P G F L L R P R G
PE7 S P D D P A F R F A P Y F T P
PE8 W R T F S R V D R A F F L
M1a A D S A Q D S T
M2a Y Q Q M D P G W
M3a Y K K D W A F A
Note. Residues shown in bold are identical to the native pre-S1 28–35 sequence; residues shown in italics indicate conservative changes. The
common motif shared by the mimotopes and the pre-S1 epitope are boxed. Numbers in parentheses refer to the total number of clones isolated
with the same sequence.
a Peptide sequences that were isolated using the synthetic peptide library.
with the sequence DPAF. The motif DPGW is almost the surface of filamentous phage adopt an appropriate
conformation which mimics the conformation of the na-identical to DPAF; pepscan analysis has shown that the
tive epitope on the pre-S1 protein.alanine can be substituted by a glycine without loss in
Synthetic peptides representing phage mimotopes PC12,antibody binding and similarly phenylalanine could be
PC9, PC4, and 5P1 were tested for inhibition of antibodysubstituted by aromatic amino acids such as tryptophan
MA 18/7 binding to pre-S containing HBsAg particles in anbinding. The final motif DWAF possessed three residues
ELISA system; only mimotope PC4 bound directly to MAin common with the sequence DPAF.
18/7 when coated onto the solid phase (data not shown).
Competitive inhibition by ELISA As illustrated in Fig. 1B, all four mimotopes inhibited the
binding of the pre-S antibody to the native antigen. Mimo-Mimotopes were analyzed for their capacity to inhibit
tope PC4 was found to inhibit more effectively comparedthe binding between MA 18/7 and pre-S1 containing
to mimotopes PC12 and PC9, suggesting that this peptideHBsAg in an ELISA assay. The mimotope MB7, recog-
binds with higher affinity to the antibody MA 18/7 as itnized by a monoclonal antibody raised against the mea-
resembles (or mimics) more closely the native epitope seensles virus fusion protein (F. D’Mello, unpublished results),
by the antibody MA 18/7. In addition, mimotope M1 derivedwas used as a negative control; this mimotope did not
from the solid phase library also inhibited the binding ofinhibit the binding between MA 18/7 and pre-S1 con-
antibody MA 18/7 to HBsAg particles (Fig. 1B) as did ataining HBsAg. All of the pre-S1 mimotopes inhibited the
chimera peptide (CHIM-1) containing an additional T-cell
reaction between MA 18/7 and pre-S1 containing HBsAg
epitope. No inhibition was seen with the mimotope peptide
particles (Fig. 1A). The greatest inhibition was seen with
M2 (data not shown).
clones PC4, 5P2, and PF2 at 1 1 106 phage particles/ml
Immunogenicity of mimotope peptidesbut at a concentration of 1 1 104 only phage PC4, PE3,
PE5, and PE7 still gave a significant level of inhibition In the present study, the immunogenicity of the identi-
fied mimotopes was also investigated. In order to in-(Fig. 1A). This suggests that mimotopes displayed on
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FIG. 1. Competitive inhibition ELISA between HBsAg particles containing pre-S antigens coated on the solid phase and MA 18/7. (A) Competition
using cloned phage preparations expressing mimotope sequences as inhibitors. Shaded and solid bars indicate competition when using 106 and
104 phage particles, respectively. (B) Synthetic peptide mimotopes derived from phage and solid phase libraries used as competitors.
crease the immunogenicity of mimotopes and overcome ies in defining the nature of important B-cell antigenic
sites and, moreover, their potential to act as immuno-immune unresponsiveness, mimotopes were either
coimmunized with an unrelated immunogenic peptide or gens.
During the course of this study findings were pub-presented as immunogens displayed on a phage clone.
Immunization of mice with the phage-displayed mimo- lished by Germaschewski and Murray (1995) using a
hexapeptide library. As with our data, the presence oftopes resulted in the induction of strong anti-phage anti-
body responses (Table 3). High levels of antibody to the the aspartyl-proline doublet was common to all the mimo-
topes analyzed. Our results extend these findings by usehomologous peptide were detected when peptide mimo-
topes were coimmunized with a T-helper cell epitope of a 15-mer phage library and independently by use of an
8-mer solid phase library. These results taken together(Table 3).
Free mimotopes 5P1 and PC4 administered without display that a wider spectrum of permissible amino acid
substitutions is possible than suggested by the data ofthe T-helper cell epitope were not immunogenic. How-
ever, mimotopes PC9 and PC12 were found to be immu- Germaschewski and Murray (1995). Furthermore, we
have shown direct competition between the phage mimo-nogenic when immunized alone in adjuvant, with mimo-
tope PC9 being the more immunogenic (Table 3). This topes and pre-S sequences on expressed HBsAg par-
ticles.suggests that these sequences contain a T-helper cell
epitope(s) for the mouse haplotype H-2d. However, anti- It is possible that amino acids from the pre-S2 region
may also contribute to the discontinuous epitope recog-body responses after coimmunization were greater.
These findings are in agreement with previous observa- nized by these monoclonal antibodies, as evidenced from
the pepscan analyses. That two regions may contributetions on the immunogenicity of phage-displayed mimo-
topes (Meola et al., 1995; Willis et al., 1993) as well as to the conformational dependency of these epitopes is
empirically strengthened by the close proximity of theovercoming unresponsiveness by coimmunization with
immunogenic peptides (Partidos and Steward, 1990). pre-S1 and pre-S2 domains with the pre-S region as pre-
dicted by a model of secondary structure folding, ob-When anti-mimotope antibodies were analyzed for anti-
gen specificity, a weak cross-reactivity with the pre-S tained by use of a multiple alignment program (Howard
et al., 1991).containing HBsAg particles was observed. These find-
ings highlight the effectiveness of random phage librar- In conclusion, the findings in this report highlight the
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TABLE 3
Immunogenicity of Phage-Displayed Pre-S Mimotopes (A) and Peptide Mimotopes (B)
Antibody titer
Immunogen Anti-mimotope Anti-preS 20–45 Anti-preS HBsAg Anti-phage
(A) Phagea
phage 5P1
In CBA mice 1.94 2.04 1.84 4.86
In C57/Bl6 mice 2.07 2.18 1.76 4.74
Phage PC4 2.20 2.41 2.46 5.28
Phage PC9 1.95 2.27 2.29 4.70
Phage PC12 1.81 2.07 2.07 4.06
(B) Peptidesb
Mimotope 5P1
Free peptide 1 1 1 ndc
Coimmunizedd nd nd nd nd
Mimotope PC4
Free peptide 1 1 1 nd
Coimmunized 2.42 1.53 1.41 nd
Mimotope PC9
Free peptide 3.55 2.12 2.25 nd
Coimmunized 4.12 2.18 2.85 nd
Mimotope PC12
Free peptide 1.72 2.00 1.89 nd
Coimmunized 2.29 2.23 2.16 nd
a With the exception of phage 5P1, all immunizations were performed in BALB/c mice.
b All immunizations were performed in BALB/c mice.
c Not determined.
d Coimmunized with measles virus T-cell epitope 258–277.
P., Chiron, J., and Diop Mar, I. (1988). Anti-preS2 antibodies in naturalpotential of combinatorial libraries for the elucidation of
hepatitis B virus infection and after immunization. Vaccine 6, 357–the primary structure of the hepatocyte domain of the pre-
361.
S molecule. Moreover, the identification of mimotopes of Coursaget, P., Lesage, G., Le Cann, P., Mayelo, V., and Bourdil, C.
conformational depend epitopes from pre-S can be used (1991). Mapping of linear B-cell epitopes of hepatitis B surface anti-
as components in a future synthetic peptide vaccine gen. Res. Virol. 142, 461–467.
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